Key result
A bibliometric analysis of 1,245 articles from 1990 to 2021 revealed that VTE prophylaxis research hotspots shifted from heparin to factor Xa inhibitors, direct thrombin inhibitors, and aspirin.
Why the study?
Venous thromboembolism after hip or knee arthroplasty has attracted increasing attention, but no bibliometric report existed on publications in this field.
This bibliometric analysis highlights the evolution of VTE research after arthroplasty, showing a transition in focus from traditional anticoagulants to direct oral anticoagulants, aspirin, and individualized risk assessment.
Tracks evolving VTE prophylaxis research priorities; leaves open whether shifts should inform clinical guidelines or practice.
BACKGROUND Venous thromboembolism (VTE) after hip or knee arthroplasty has attracted increasing attention over the past few decades. However, there is no bibliometric report on the publications in this field. OBJECTIVE The purpose of this study was to analyze the global research status, hotspots, and trends in VTE after arthroplasty. METHODS All articles about VTE research after hip or knee arthroplasty from 1990 to 2021 were retrieved from the Web of Science Core Collection database. The information of each article including citation, title, author, journal, country, institution, and keywords, was extracted for bibliometric analysis. RESULTS A total of 1,245 original articles from 53 countries and 603 institutions were retrieved. The number of publications showed a rising trend, with the largest contributions made by the USA. McMaster University in Canada was the leading institution for publications. The most productive author in this field was Eriksson BI, followed by Lassen MR and Dahl OE. The journals with the highest output and highest citation were the Journal of Arthroplasty and the Thrombosis and Haemostasis, respectively. The research hotspots switched from VTE diagnosis and heparin to factor Xa inhibitors (fondaparinux, rivaroxaban, apixaban) and direct thrombin inhibitors (dabigatran etexilate, ximelagatran), and finally to aspirin, risk factor studies, which can be observed from the keyword analysis and co-cited reference cluster analysis. CONCLUSIONS Over the past few decades, the understanding of VTE after hip or knee arthroplasty has been improved significantly. VTE prophylaxis agents have attracted tremendous attention, including warfarin, low molecular weight heparin, oral direct factor Xa inhibitors, oral direct thrombin inhibitors, and aspirin. These studies exert a critical influence on decision-making and management for VTE. Additionally, individualized VTE prevention based on risk factors for each patient and the development of new safe, effective, and inexpensive oral agents will be emerging trends in the future.
No takes yet. Share an insight, caveat, or question.
Song et al. (2021) conducted a review in Venous thromboembolism after hip or knee arthroplasty. VTE research publications was evaluated on Global research status, hotspots, and trends in VTE after arthroplasty. A bibliometric analysis of 1,245 articles from 1990 to 2021 revealed that VTE prophylaxis research hotspots shifted from heparin to factor Xa inhibitors, direct thrombin inhibitors, and aspirin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: